Advanced Magnetics seeks US trials for agent:
This article was originally published in Clinica
Advanced Magnetics has filed an application with the FDA to begin Phase I clinical trials in the US of its new MRI contrast agent, under an investigational drug exemption. The agent, currently known as Code 7228, will be evaluated in magnetic resonance angiography for the detection of blood flow in the heart muscle and as a next-generation lymph node agent. The Cambridge, Massachusetts-based company said the product was a potential competitor to Epix Medical's MS-325 MRA contrast agent and Nycomed Amersham's NC100150 MRI contrast agent.